Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Busby, E. C.
Right arrow Articles by Sarkaria, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Busby, E. C.
Right arrow Articles by Sarkaria, J. N.
[Cancer Research 60, 2108-2112, April 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

The Radiosensitizing Agent 7-Hydroxystaurosporine (UCN-01) Inhibits the DNA Damage Checkpoint Kinase hChk11

Ericka C. Busby, Dru F. Leistritz, Robert T. Abraham, Larry M. Karnitz and Jann N. Sarkaria2

Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905 [E. C. B., D. F. L., L. M. K., J. N. S.], and Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710 [R. T. A.]

The investigational anticancer agent 7-hydroxystaurosporine (UCN-01) abrogates the G2 checkpoint in tumor cells and sensitizes them to the lethal effects of genotoxic anticancer agents. On the basis of the role of the Cdc25C phosphatase in maintenance of this damage-inducible checkpoint, we hypothesized that UCN-01 inhibits a component of the signal transduction pathway that modulates Cdc25C phosphorylation. Of the three kinases known to phosphorylate Cdc25C on Ser216, both checkpoint kinase 1 (hChk1) and Cdc25C-associated protein kinase 1 (cTAK1) were potently inhibited by UCN-01 with IC50s of 11 and 27 nM, respectively. Treatment of K562 erythroblastoid leukemia cells with similar drug concentrations resulted in decreased levels of Ser216 phosphorylation of Cdc25C and complete disruption of the {gamma}-radiation-induced G2 checkpoint. In contrast to hChk1, the hChk2 kinase was 100-fold more resistant to inhibition by UCN-01 (IC50, 1040 nM). These results suggest that disruption of the DNA damage-induced G2 checkpoint by UCN-01 is mediated through the inhibition of the Cdc25C kinases, hChk1 and cTAK1, and that hChk2 activity is not sufficient to enforce the G2 checkpoint in cells treated with a pharmacological inhibitor of hChk1.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Ashwell and S. Zabludoff
DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
Clin. Cancer Res., July 1, 2008; 14(13): 4032 - 4037.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Pabla, S. Huang, Q.-S. Mi, R. Daniel, and Z. Dong
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
J. Biol. Chem., March 7, 2008; 283(10): 6572 - 6583.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al.
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo
Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. A. Levesque, A. A. Fanous, A. Poh, and A. Eastman
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest
Mol. Cancer Ther., February 1, 2008; 7(2): 252 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. A. Seiler, C. Conti, A. Syed, M. I. Aladjem, and Y. Pommier
The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses
Mol. Cell. Biol., August 15, 2007; 27(16): 5806 - 5818.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Zhang, Y. Zhou, S. Trusa, X. Meng, E. Y. C. Lee, and M. Y. W. T. Lee
A Novel DNA Damage Response: RAPID DEGRADATION OF THE p12 SUBUNIT OF DNA POLYMERASE {delta}
J. Biol. Chem., May 25, 2007; 282(21): 15330 - 15340.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Wilsker and F. Bunz
Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival
Mol. Cancer Ther., April 1, 2007; 6(4): 1406 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Ewald, D. Sampath, and W. Plunkett
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation
Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J. Z. Wu, and D. Delia
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2
Mol. Cancer Ther., March 1, 2007; 6(3): 935 - 944.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. A. Levesque and A. Eastman
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Carcinogenesis, January 1, 2007; 28(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Kedde, C. le Sage, A. Duursma, E. Zlotorynski, B. van Leeuwen, W. Nijkamp, R. Beijersbergen, and R. Agami
Telomerase-independent Regulation of ATR by Human Telomerase RNA
J. Biol. Chem., December 29, 2006; 281(52): 40503 - 40514.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. P. Perez, L. D. Lewis, A. P. Beelen, A. J. Olszanski, N. Johnston, C. H. Rhodes, B. Beaulieu, M. S. Ernstoff, and A. Eastman
Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850)
Clin. Cancer Res., December 1, 2006; 12(23): 7079 - 7085.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
B. Jaklevic, L. Uyetake, W. Lemstra, J. Chang, W. Leary, A. Edwards, S. Vidwans, O. Sibon, and T. Tin Su
Contribution of Growth and Cell Cycle Checkpoints to Radiation Survival in Drosophila
Genetics, December 1, 2006; 174(4): 1963 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. C. S. Chini and J. Chen
Repeated Phosphopeptide Motifs in Human Claspin Are Phosphorylated by Chk1 and Mediate Claspin Function
J. Biol. Chem., November 3, 2006; 281(44): 33276 - 33282.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
V. Leung-Pineda, C. E. Ryan, and H. Piwnica-Worms
Phosphorylation of Chk1 by ATR Is Antagonized by a Chk1-Regulated Protein Phosphatase 2A Circuit
Mol. Cell. Biol., October 15, 2006; 26(20): 7529 - 7538.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan
Development of a screening assay for surrogate markers of chk1 inhibitor-induced cell cycle release.
J Biomol Screen, October 1, 2006; 11(7): 792 - 806.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
K. M. Comess, J. D. Trumbull, C. Park, Z. Chen, R. A. Judge, M. J. Voorbach, M. Coen, L. Gao, H. Tang, P. Kovar, et al.
Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1
J Biomol Screen, October 1, 2006; 11(7): 755 - 764.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. H. Arlander, S. J. Felts, J. M. Wagner, B. Stensgard, D. O. Toft, and L. M. Karnitz
Chaperoning Checkpoint Kinase 1 (Chk1), an Hsp90 Client, with Purified Chaperones
J. Biol. Chem., February 3, 2006; 281(5): 2989 - 2998.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Seo, T. Yan, J. E. Schupp, K. Yamane, T. Radivoyevitch, and T. J. Kinsella
The Interaction between Two Radiosensitizers: 5-Iododeoxyuridine and Caffeine
Cancer Res., January 1, 2006; 66(1): 490 - 498.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz and M. A. Shah
Targeting the Cell Cycle: A New Approach to Cancer Therapy
J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. L. Clarke, L. N. Bennett, and P. R. Clarke
Cleavage of Claspin by Caspase-7 during Apoptosis Inhibits the Chk1 Pathway
J. Biol. Chem., October 21, 2005; 280(42): 35337 - 35345.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Liu, Y. Guo, Y. Li, Y. Jiang, S. Chubb, A. Azuma, P. Huang, A. Matsuda, W. Hittelman, and W. Plunkett
Molecular Basis for G2 Arrest Induced by 2'-C-Cyano-2'-Deoxy-1-{beta}-D-Arabino-Pentofuranosylcytosine and Consequences of Checkpoint Abrogation
Cancer Res., August 1, 2005; 65(15): 6874 - 6881.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Lara Jr, P. C. Mack, T. Synold, P. Frankel, J. Longmate, P. H. Gumerlock, J. H. Doroshow, and D. R. Gandara
The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial
Clin. Cancer Res., June 15, 2005; 11(12): 4444 - 4450.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
J. Biol. Chem., April 8, 2005; 280(14): 14349 - 14355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. K. Mukhopadhyay, A. M. Senderowicz, and G. Ferbeyre
RNA Silencing of Checkpoint Regulators Sensitizes p53-Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells
Cancer Res., April 1, 2005; 65(7): 2872 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. L. Maude and G. H. Enders
Cdk Inhibition in Human Cells Compromises Chk1 Function and Activates a DNA Damage Response
Cancer Res., February 1, 2005; 65(3): 780 - 786.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
M. Urist, T. Tanaka, M. V. Poyurovsky, and C. Prives
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2
Genes & Dev., December 15, 2004; 18(24): 3041 - 3054.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. B. Kondapaka, M. Zarnowski, D. R. Yver, E. A. Sausville, and S. W. Cushman
7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation: A Basis for Decreased Insulin-Stimulated Glucose Transport
Clin. Cancer Res., November 1, 2004; 10(21): 7192 - 7198.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Essmann, I. H. Engels, G. Totzke, K. Schulze-Osthoff, and R. U. Janicke
Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of p53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event
Cancer Res., October 1, 2004; 64(19): 7065 - 7072.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Jiang, B. Zhao, R. Britton, L. Y. Lim, D. Leong, J. S. Sanghera, B.-B. S. Zhou, E. Piers, R. J. Andersen, and M. Roberge
Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide
Mol. Cancer Ther., October 1, 2004; 3(10): 1221 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Wang, T. Wiltshire, Y. Wang, C. Mikell, J. Burks, C. Cunningham, E. S. Van Laar, S. J. Waters, E. Reed, and W. Wang
ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven
J. Biol. Chem., September 17, 2004; 279(38): 39584 - 39592.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. Tse and G. K. Schwartz
Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe
Cancer Res., September 15, 2004; 64(18): 6635 - 6644.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
S. Sengupta, A. I. Robles, S. P. Linke, N. I. Sinogeeva, R. Zhang, R. Pedeux, I. M. Ward, A. Celeste, A. Nussenzweig, J. Chen, et al.
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest
J. Cell Biol., September 13, 2004; 166(6): 801 - 813.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Kondo, M. Kobayashi, J. Tanaka, A. Yokoyama, S. Suzuki, N. Kato, M. Onozawa, K. Chiba, S. Hashino, M. Imamura, et al.
Rapid Degradation of Cdt1 upon UV-induced DNA Damage Is Mediated by SCFSkp2 Complex
J. Biol. Chem., June 25, 2004; 279(26): 27315 - 27319.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Stojic, N. Mojas, P. Cejka, M. di Pietro, S. Ferrari, G. Marra, and J. Jiricny
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase
Genes & Dev., June 1, 2004; 18(11): 1331 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
M. Melixetian, A. Ballabeni, L. Masiero, P. Gasparini, R. Zamponi, J. Bartek, J. Lukas, and K. Helin
Loss of Geminin induces rereplication in the presence of functional p53
J. Cell Biol., May 24, 2004; 165(4): 473 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann
Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death
J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Meng, Y. Yuan, A. Maestas, and Z. Shen
Recovery from DNA Damage-induced G2 Arrest Requires Actin-binding Protein Filamin-A/Actin-binding Protein 280
J. Biol. Chem., February 13, 2004; 279(7): 6098 - 6105.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
J. R. A. Hutchins, D. Dikovskaya, and P. R. Clarke
Regulation of Cdc2/Cyclin B Activation in Xenopus Egg Extracts via Inhibitory Phosphorylation of Cdc25C Phosphatase by Ca2+/Calmodium-dependent Kinase II
Mol. Biol. Cell, October 1, 2003; 14(10): 4003 - 4014.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. C. S. Chini and J. Chen
Human Claspin Is Required for Replication Checkpoint Control
J. Biol. Chem., August 8, 2003; 278(32): 30057 - 30062.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Roshal, B. Kim, Y. Zhu, P. Nghiem, and V. Planelles
Activation of the ATR-mediated DNA Damage Response by the HIV-1 Viral Protein R
J. Biol. Chem., July 3, 2003; 278(28): 25879 - 25886.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Amico, A. M. Barbui, E. Erba, A. Rambaldi, M. Introna, and J. Golay
Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3
Blood, June 1, 2003; 101(11): 4589 - 4597.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Furuta, H. Takemura, Z.-Y. Liao, G. J. Aune, C. Redon, O. A. Sedelnikova, D. R. Pilch, E. P. Rogakou, A. Celeste, H. T. Chen, et al.
Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes
J. Biol. Chem., May 23, 2003; 278(22): 20303 - 20312.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. S. Weiss, P. Leder, and C. Vaziri
Critical Role for Mouse Hus1 in an S-Phase DNA Damage Cell Cycle Checkpoint
Mol. Cell. Biol., February 1, 2003; 23(3): 791 - 803.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
H. Miao, J. A. Seiler, and W. C. Burhans
Regulation of Cellular and SV40 Virus Origins of Replication by Chk1-dependent Intrinsic and UVC Radiation-induced Checkpoints
J. Biol. Chem., January 31, 2003; 278(6): 4295 - 4304.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. A. Kohn, C. J. Yoo, and A. Eastman
The Protein Kinase C Inhibitor Go6976 Is a Potent Inhibitor of DNA Damage-induced S and G2 Cell Cycle Checkpoints
Cancer Res., January 1, 2003; 63(1): 31 - 35.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. Okubo, J. M. Lehman, and T. D. Friedrich
Negative Regulation of Mitotic Promoting Factor by the Checkpoint Kinase Chk1 in Simian Virus 40 Lytic Infection
J. Virol., December 20, 2002; 77(2): 1257 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. P. Heffernan, D. A. Simpson, A. R. Frank, A. N. Heinloth, R. S. Paules, M. Cordeiro-Stone, and W. K. Kaufmann
An ATR- and Chk1-Dependent S Checkpoint Inhibits Replicon Initiation following UVC-Induced DNA Damage
Mol. Cell. Biol., December 15, 2002; 22(24): 8552 - 8561.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Zhao, M. J. Bower, P. J. McDevitt, H. Zhao, S. T. Davis, K. O. Johanson, S. M. Green, N. O. Concha, and B.-B. S. Zhou
Structural Basis for Chk1 Inhibition by UCN-01
J. Biol. Chem., November 22, 2002; 277(48): 46609 - 46615.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Zhao, J. L. Watkins, and H. Piwnica-Worms
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints
PNAS, November 12, 2002; 99(23): 14795 - 14800.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Wang, G. C. Li, G. Iliakis, and Y. Wang
Ku Affects the CHK1-dependent G2 Checkpoint after Ionizing Radiation
Cancer Res., November 1, 2002; 62(21): 6031 - 6034.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Patel, T. Lahusen, C. Leethanakul, T. Igishi, M. Kremer, L. Quintanilla-Martinez, J. F. Ensley, E. A. Sausville, J. S. Gutkind, and A. M. Senderowicz
Antitumor Activity of UCN-01 in Carcinomas of the Head and Neck Is Associated with Altered Expression of Cyclin D3 and p27KIP1
Clin. Cancer Res., November 1, 2002; 8(11): 3549 - 3560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Yu, J. La Rose, H. Zhang, H. Takemura, K. W. Kohn, and Y. Pommier
UCN-01 Inhibits p53 Up-Regulation and Abrogates {gamma}-Radiation-induced G2-M Checkpoint Independently of p53 by Targeting Both of the Checkpoint Kinases, Chk2 and Chk1
Cancer Res., October 15, 2002; 62(20): 5743 - 5748.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Eastman, E. A. Kohn, M. K. Brown, J. Rathman, M. Livingstone, D. H. Blank, and G. W. Gribble
A Novel Indolocarbazole, ICP-1, Abrogates DNA Damage-induced Cell Cycle Arrest and Enhances Cytotoxicity: Similarities and Differences to the Cell Cycle Checkpoint Abrogator UCN-01
Mol. Cancer Ther., October 1, 2002; 1(12): 1067 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Sampath, Z. Shi, and W. Plunkett
Inhibition of Cyclin-Dependent Kinase 2 by the Chk1-Cdc25A Pathway during the S-Phase Checkpoint Activated by Fludarabine: Dysregulation by 7-Hydroxystaurosporine
Mol. Pharmacol., September 1, 2002; 62(3): 680 - 688.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. F.W. Frijhoff, C. J. Conti, and A. M. Senderowicz
Second Symposium of Novel Molecular Targets for Cancer Therapy
Oncologist, August 1, 2002; 7(90003): 1 - 3.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Senderowicz
The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01
Oncologist, August 1, 2002; 7(90003): 12 - 19.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. A. Kohn, N. D. Ruth, M. K. Brown, M. Livingstone, and A. Eastman
Abrogation of the S Phase DNA Damage Checkpoint Results in S Phase P